News Releases
Nov 24, 2020
ALX Oncology Announces December 2020 Virtual Investor Conference Participation Read more
Nov 16, 2020
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2 Expressing Breast Cancer Read more
Nov 12, 2020
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights Read more
Nov 9, 2020
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors Read more
Nov 5, 2020
ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting Read more
Nov 2, 2020
ALX Oncology Announces November 2020 Virtual Investor Conference Participation Read more
Oct 28, 2020
ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome Read more
Oct 14, 2020
ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Read more
Oct 6, 2020
ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board Read more
Sep 22, 2020
ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer Read more